



<b>Swiss-Prot No.:</b>	P40337
<b>Storage/Stability:</b>	Store at -20 °C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
<b>Immunogen:</b>	A synthetic peptide of human VHL
<b>Purification:</b>	Affinity purification
<b>Reactivity:</b>	Human,Mouse,Rat
<b>Other Names:</b>	—
<b>Background:</b>	Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
<b>Gene ID:</b>	7428
<b>Source:</b>	Rabbit

<b>Antibody type:</b>	Polyclonal Antibodies
<b>Isotype:</b>	IgG
<b>Molecular Weight:</b>	18kDa/19kDa/24kDa
<b>Recommended Dilutions:</b>	WB 1:500 - 1:2000 IHC 1:50 - 1:200